Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx Says New OvPlex Algorithm Beats CA125 in Avoiding False Positives

Premium

Australian diagnostics firm HealthLinx said that preliminary data from a Korean Food and Drug Administration study of its ovarian cancer diagnostic OvPlex showed that the test offers an advantage over use of CA125 alone – currently the standard biomarker test used in ovarian cancer diagnosis.

The analysis used a new diagnostic algorithm developed using data from an ongoing 1,150-patient multinational trial for OvPlex. The results suggest that OvPlex holds an advantage over CA125 alone, particularly in reducing false positives, the company said.

The preliminary analysis of the KFDA study used data from 220 patient samples. According to the company, final analysis of the KFDA trial data will occur after completion of the multinational trial and implementation of the new algorithm it is developing through that trial.

Upon completion of the trial HealthLinx plans to make a formal submission to the KFDA for regulatory approval of OvPlex. HealthLinx's partner Seoul Clinical Laboratories, which is co-funding the study, will then obtain an exclusive clinical license to distribute OvPlex in South Korea.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.